|Articles|January 12, 2006

Return to Science

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.

ByNicholas Jacobus,Gurinder S. Sidhu, MD

July 21st 2026

Developing Better Drugs, Not Just More Drugs: Q&A with David Hung

ByMike Hollan,David Hung

July 21st 2026

A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims

ByScott Warren

July 21st 2026

Gerren McHam, vice president of Government and External Affairs, API Innovation Center

What Policy Tools Move the Needle on API Manufacturing Capacity?

ByNicholas Jacobus,Gerren McHam

July 21st 2026

Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia

ByNicholas Jacobus

July 20th 2026

Return to Science

Related Content

Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.

Developing Better Drugs, Not Just More Drugs: Q&A with David Hung

A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims

What Policy Tools Move the Needle on API Manufacturing Capacity?

Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia

Trending on PharmExec

How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?

Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory

Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia

Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D

FDA Clears Consano’s IND for C-1101